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Although dermal fibroblasts are one of the first cell types exposed to West 
Nile virus (WNV) during a blood meal by an infected mosquito, little is known about 
WNV replication within this cell type. Here, I demonstrate that pathogenic, WNV-
New York (WNV-NY), and nonpathogenic, WNV-Australia (WNV-AUS60) strains 
are able to infect and replicate in primary human dermal fibroblasts (HFFs).  
However, WNV-AUS60 replication and spread within HFFs was reduced compared 
to that of WNV-NY due to an interferon-independent reduction in viral infectivity 
early in infection.  Additionally, replication of both strains was constrained late in 
infection by an IFN-β-dependent reduction in particle infectivity.  Overall, our data 
indicate that dermal fibroblasts are capable of supporting WNV replication; however, 
the low infectivity of particles produced from HFFs late in infection suggests that this 
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Chapter 1: Introduction 
1. WNV History 
West Nile virus (WNV) is a positive-sense single-stranded RNA virus in 
the family Flaviviridae. This family is made up of three genera: Hepacivirus, 
Pestivirus, and Flavivirus.  WNV belongs to the genus Flavivirus; other members 
include yellow fever virus, dengue virus, and tick-borne encephalitis virus.  WNV 
was first isolated from a febrile woman in Uganda in 1937 [1].  By the 1960s, 
WNV spread to humans and horses in the Middle East, Europe, Australia and 
Asia where it caused a mild fever known as WN fever with few cases of 
encephalitis [2-7].  Further spread in the 1990s led to outbreaks in Algeria, 
Morocco, Tunisia, Italy, and Israel, contributing to encephalitis and death in 
humans and horses [8-15].  By studying WNV seroprevalence in birds, 
correlations were drawn between the movement of migratory birds and spread of 
the virus [16-17].     
In 1999 in New York, veterinarians noted unusually high numbers of dead 
crows with detectable virus in their brains.  Virus was isolated from the dead birds 
and later identified as WNV [18].  Between 1999 and 2000, 83 human cases were 
reported in New York, Connecticut, and New Jersey.  The virus quickly spread 
and in 2002, there were reports of 4,156 cases in 38 states [19].  Since emerging 
in the United States, WNV infections have been confirmed in every state of the 
continental United States. Compared to previous outbreaks in African countries, 




increase in both the number of reported cases and the severity of disease [20]. 
WNV is now the leading cause of mosquito-borne neuroinvasive disease in the 
United States.  Between 1999 and 2013, over 17,000 cases with neurological 
complications, such as meningitis, encephalitis, and acute flaccid paralysis and 
over 1,600 deaths due to WNV, were reported [19].  While there are approved 
vaccines for horses, there is still no approved vaccine or treatment for WNV in 
humans. 
 
2. WNV transmission 
The transmission cycle of WNV was first reported by a study conducted 
on the ecology of WNV in Egypt and southern Sudan published in 1956 [6].  
Surveying human blood from approximately 1,500 people in Egypt and southern 
Sudan, they determined that over 50% of the samples were seropositive for WNV.  
The widespread prevalence of WNV in humans in the area led to the study of 
various birds and arthropods to discover the mode of transmission.  Many species 
of birds tested positive for WNV, but mosquitoes were the only WNV-positive 
arthropods out of the 26,000 sampled [6].  This study demonstrated that the 
transmission cycle of WNV utilizes mosquitos as vectors and birds as hosts 
(Figure 1).  Several genuses of mosquitoes can transmit WNV and many avian 
species can serve as reservoirs, but in the United States Culex mosquitoes are 
known to be the primary vector and robins have been identified as the most 






Figure 1. WNV transmission cycle 
WNV is transmitted by a mosquito vector and birds serve as the reservoir of the 






Culex mosquitoes are present in all of the Americas and have the highest 
populations in seasons of high temperature and heavy rain.  Viral transmission is 
also high when water is scarce because mosquitoes and birds drink from the same 
pools of water [22].  Straying from the transmission cycle, mosquitoes can also 
infect dead-end hosts such as humans and horses.  It is thought that levels of 
viremia in these hosts are very low, which does not allow for transmission back to 
the mosquito [23]. 
 
3. WNV genome, structure, and proteins 
West Nile virus (WNV) is a positive-sense single-stranded RNA virus 
with a 5’ cap.  Its genome is approximately 11 kb in length and consists of a 
single open reading frame encoding three structural proteins (Capsid, 
Premembrane/membrane, and Envelope) and seven nonstructural proteins (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B, and NS5).  The genome is flanked by 5’ and 3’ 
nontranslated regions (NTRs) (Figure 2).   
WNV virions are small, spherical and enveloped.  Early cryo-electron 
microscopy (cryo-EM) images suggested that both the nucleocapsid and the 
envelope had icosahedral symmetry [24].  However, later studies using improved 
cryo-EM technology show that the nucleocapsid has no discernable symmetry 
[25]. The nucleocapsid is composed of capsid (C) proteins, which coat the viral 






Figure 2. WNV genome 
The 11 kb genome encodes 3 structural proteins and 7 nonstructural (NS) proteins 




While the WNV structural proteins are integral parts of the envelope and 
capsid, the nonstructural proteins serve functions related to viral RNA synthesis.  
Studies focusing on NS1 suggest it has a role in viral RNA replication since it has 
been shown to colocalize with viral replication complexes [26, 27].  Further 
supporting this work, neither (+) nor (-) strand viral RNA could accumulate in the 
absence of NS1 [28].  The secreted form of NS1 can be detected in the blood of 
viremic hosts and has been linked to disease severity in a hamster model [29].  In 
addition to being secreted, NS1 associated with cell surfaces has been shown to 
protect the cell from complement-mediated lysis by binding to glycoprotein factor 
H, which is known to regulate the alternative complement pathway [30]. 
Specific functions of NS2A, NS2B, NS4A, and NS4B have not been fully 
characterized.  Studies focusing on NS2A suggest that this protein participates in 
viral assembly [31, 32].  In complex with NS3, NS2B is a required cofactor for 
serine protease activity of NS3 [33].  The serine protease activity domain of NS3 
exists at the N-terminus of the protein and functions to cleave the polyprotein into 
individual proteins [34-37].  The C-terminus of NS3 contains RNA helicase, 
nucleoside triphosphatase (NTPase), and RNA triphosphatase (RTPase) motifs, 
which are important for RNA replication [38-40]. 
WNV and dengue virus (DENV) NS4A contain amino acid residues that 
act as a signal sequence for the translocation of NS4B into the lumen of the ER 
(named the C-terminal transmembrane domain 2K), were both shown to induce 
cytoplasmic membrane rearrangement [41-43].  This rearrangement resembled the 




cells.  Molecular dynamics computer simulations of DENV NS4A have shown 
that this protein has membrane-altering properties [44].  Both WNV NS4A and 
NS4B have been reported to block innate immune signaling [45-47].  Like NS3, 
NS5 is also known to have several functions.  In addition to its role of partially 
blocking the innate immune cascade, the N-terminal region of the protein encodes 
a methyl transferase, which is required for viral RNA capping [48]. The C-
terminal portion of NS5 contains the viral RNA-dependent RNA polymerase [49-
53]. 
 
4. WNV classification 
Based on the sequence of the structural proteins, WNV has been classified 
into five lineages and two clades that differ from each other by 20-27% (Figure 3) 
[54, 55].  Lineages one and two are the two main lineages; they include both 
highly pathogenic and less pathogenic strains of the virus [56-60]. Lineage one 
strains have been isolated from the United States, Europe, Israel, Africa, Russia, 
and Australia. While lineage two strains were initially identified in sub-Saharan 
Africa and Madagascar, they have recently also been detected in Eastern and 





Figure 3. WNV classification 
WNV is grouped into five lineages, labeled 1-5 on the left, and 2 clades (1a and 
1b). Phylogenetic analysis of selected WNV strains compared sequences of the E 
region of the WNV genome in a nearest neighbor joining tree. Strains listed are 
representative of each lineage and include isolates from around the globe. JEV 
serves as an outgroup. Figure adapted from Lanciotti 2002, Bondre 2007, and 





5. WNV life cycle 
WNV can replicate in many different avian, mammalian, amphibian, and 
insect cell types.  Known receptors that can mediate WNV attachment include 
DC-SIGN, DC-SIGNR, and αVβ3 integrins [71-73]. Unknown receptors also exist 
because WNV can infect cell types lacking these receptors.  Following 
attachment, WNV is internalized via receptor-mediated endocytosis of a clathrin-
coated pit [71, 74] (Figure 4).  As the endosome acidifies, the virus membrane 
fuses with the endosomal membrane and the nucleocapsid enters the cell [75, 76]. 
The genome is uncoated and translated by the host cell ribosome as a polyprotein.  
The polyprotein is co- and post-translationally cleaved into ten separate proteins 
by viral and cellular proteases.  Transcription of minus-strand RNA from positive-
strand RNA utilizes the RNA-dependent RNA polymerase (RdRp), NS5. While 
the minus strand is sequestered in replication complexes [49, 77-79], it serves as 
the template for genomic RNA synthesis [80]. Nonstructural proteins induce the 
formation of the endoplasmic reticulum (ER) membrane invaginations that house 
the replication complexes [41-44].   
 In association with ER membranes, viral genomes can be translated, 
replicated, or assembled into a virion.  E and prM have transmembrane domains 
that insert into the ER membrane such that their exodomains are located in the ER 
lumen.  When membrane-associated capsid dimers interact with viral genomic 
RNA in areas where E and prM are inserted, immature virions bud into the ER 






Figure 4. WNV life cycle 
The virion attaches and enters the target cell through receptor-mediated 
endocytosis.  Uncoating from an endosomal vesicle occurs in a pH-dependent 
manner.  This is followed by polyprotein translation, polyprotein cleavage into 
individual proteins, and replication of the viral genome.  The virus particle is 
assembled, buds through the ER membrane, moves through the Golgi and trans-





the fusion peptide on E [24, 82].  In order for the particle to mature, the pr portion 
of prM must be cleaved by a cellular furin-like protease in the trans-Golgi 
compartment [83].  In the mature conformation, the E trimers rearrange into 
antiparallel dimers, which makes them fusion competent [84-86].  After 10 to 12 
hours in a mammalian cell, virions are finally exocytosed and mature or partially 
mature particles are capable of infecting other cells [22, 87]. 
 
6. WNV dissemination pathway 
Infection of human hosts occurs during a WNV-infected mosquito’s blood 
meal, where it inserts its proboscis through the epidermis and into the dermis.  
Probing for a blood vessel, the mosquito salivates and deposits high levels of 
WNV along with factors that can enhance infection [88-91].  While keratinocytes, 
the major cell type comprising the epidermal layer of the skin, have been shown 
to support high levels of WNV replication [90], primary human dermal fibroblasts 
are also capable of sustaining the replication of WNV and several other 
Flaviviruses [92].  Langerhans dendritic cells and neutrophils traffic to the site of 
infection, take up the pathogen, and transport it to the draining lymph node and 
other secondary lymphoid organs [93-96].  The virus then spreads through the 
circulatory system and subsequent viremia leads to infection of other organs such 





7. Innate immune recognition of WNV 
When a host encounters a viral pathogen, the first line of defense is the 
innate intracellular immune system.  The cell’s pattern recognition receptors 
(PRRs) can detect pathogen associated molecular patterns (PAMPs) and induce 
the expression of antiviral genes.  One PAMP is double-stranded (ds)RNA; initial 
reports demonstrated that Toll-like receptor 3 (TLR3) recognized this PAMP 
when it was extracellular or within an endosome [97].  Studies using TLR3-
deficient mice showed that the mice succumbed to infection by murine 
cytomegalovirus (MCMV), but they remained resistant to infections by some 
other viruses such as lymphocytic choriomeningitis virus (LCMV), vesicular 
stomatatis virus (VSV) and reovirus [98].  In addition, the introduction of 
(ds)RNA in the cytoplasm of TLR3-deficient cells has also been shown to 
stimulate the host antiviral response [99, 100].  Combined, these studies showed 
that TLR3 was not required for an effective host antiviral response to some 
pathogens and suggested that other PRRs existed. 
A more recently discovered PRR is retinoic acid-inducible gene 1 (RIG-I), 
which is a DexD/H RNA helicase that was identified as an essential regulator for 
poly(rI):poly(rC)-induced signaling in a functional screen [101].  Later in vitro 
studies showed that RIG-I bound to intracellular poly(rI):poly(rC) [51, 102].  
These studies also identified other genes that encode RIG-I related proteins: 
melanoma differentiation associated gene 5 (MDA5) and laboratory of genetics 
and physiology 2 (LGP2) [51, 102].  This class of intracellular PRRs is now 




TLR3, RIG-I, and MDA5 pathways activate various signaling cascades to 
lead to the activation and nuclear translocation of nuclear factor-kappa B (NF-κB) 
and interferon regulatory factor-3 (IRF-3) (Figure 5) [103-116].  IRF-3, NF-κB, 
and c-jun/ATF-2 assemble on the IFN-β promoter to form the enhanceosome and 
induce IFN-β production [117]. 
IFN-β is secreted from cells and binds to the IFN-α/β receptor in either an 
autocrine or paracrine manner, to activate the Janus kinase (JAK)/signal 
transducers and activators of transcription (STAT) (JAK/STAT) signaling 
pathway (Figure 5) [118].  The IFN-α/β receptor is made up of IFNAR-1 and 
IFNAR-2, which are associated with Tyk2 and JAK1, respectively. Tyk2 and 
JAK1 become phosphorylated following IFN-β binding to the receptor.  This 
triggers downstream formation and phosphorylation of the stable STAT1-STAT2 
heterodimer.  The dimerization and phosphorylation of this complex leads to a 
conformational change, attributing to the exposure a of nuclear localization signal 
(NLS) [119].  This STAT1-STAT2 heterodimer complexes with IRF-9 to form 
the ISGF3 heterotrimer and translocates to the nucleus [120].  ISGF3 then binds 
to the IFN-stimulated responsive element (ISRE), which is present on the 
promoter of most IFN-stimulated genes (ISGs) [121].  ISGs include proteins with 
direct antiviral effects such as ISG15, ISG56 and 2′,5′-oligoadenylate synthetase 
(OAS); components involved in antigen presentation; RLRs and TLRs; 
transcription factors such as IRF-1, IRF-7 and IRF-9; and proinflammatory 





Figure 5. Innate immune signaling 
WNV PAMPs are recognized by PRRs such as RIG-I, MDA-5, or TLR3.  This 
triggers the activation of transcription factors that translocate to the nucleus and 
promote the transcription of IFN-β, IFN-α, or a subset of ISGs.  Secreted IFN-β 
and IFN-α can act in an autocrine or paracrine manner by binding to the IFN-α/β 
receptor and triggering the JAK/STAT pathway.  This leads to the activation of 
the transcription factor ISGF3, which translocates to the nucleus and induces the 




continued infection leads to the production of IFN-α [127, 129, 130].  Like 
IFN-β, IFN-α is secreted from cells and binds to the IFN-α/β receptor to activate 
the JAK/STAT signaling cascade [118].  Ultimately, ISG expression controls 
infections and triggers an antiviral state within the cell. 
 While the production of ISGs typically follows IFN induction, ISGs can 
also be produced directly following viral infection of cells (Figure 5) [129, 131-
136].  A study by Grandvaux et al. identified that a subset of ISGs, including 
ISG15, ISG54, ISG56, and ISG60, could be transcribed following IRF-3 
activation [137].  This subset of ISGs is involved in the establishment of an 
antiviral state prior to and following IFN signaling. 
 
8. WNV evasion and inhibition of the innate immune response 
In response to the host cell developing mechanisms to detect and block 
WNV infection, WNV has evolved means to evade innate intracellular antiviral 
responses and block JAK/STAT signaling.  While WNV can be recognized by 
TLR3, RIG-I, and MDA-5, the first PRR to detect WNV in most mammalian cell 
types is RIG-I [138, 139]. However, WNV evades detection by RIG-I by masking 
viral PAMPs until later times post infection.  Consequently, downstream IRF-3 
activation is delayed until approximately 12 to 16 h post-infection [140].   
Evading detection by a cell’s defenses allows WNV to replicate before the cell 
can suppress translation or block viral replication [139].  RNA segments in both 
the WNV genome and antigenome have been found to trigger a RIG-I-specific 




their stimulatory capacity.  This suggests that the ability of WNV to evade the 
host antiviral response lies in its ability to sequester these stimulatory segments of 
viral RNA [141]. 
In addition to evading innate antiviral responses, many structural and 
nonstructural WNV proteins have been found to act in different ways to prevent 
or inhibit JAK/STAT signaling (Figure 6).  Measuring the induction of ISGs 
following infection with WNV, it was noted that the host antiviral response was 
attenuated [140].  ISGs are typically induced following JAK/STAT signaling, 
which requires the type-I IFNs, IFN-α/-β, to be secreted from infected cells.  If 
signaling through PRRs is inhibited, IFN-β will not be produced and the 
JAK/STAT pathway will not be initiated.  TLR-3 signaling may be inhibited by 
the viral NS1 protein or by specific E protein glycosylation profiles [142, 143].  
However, a separate study showed that neither WNV nor DENV NS1 was able to 
disrupt TLR3 signaling [144].  In the less pathogenic strain of WNV, Kunjin virus 
(KUNV), NS2A has been found to specifically inhibit IFN-β transcription while 
the introduction of the NS2A A30P mutation leads to rapid IFN-β production [45, 
47]. 
Comparing highly pathogenic to less pathogenic strains of WNV, the 
ability of a strain to control IFN and JAK/STAT signaling proved to be a distinct 
characteristic of highly virulent strains [145].  Some studies have found that 
WNV NS5 can inhibit phosphorylation of Tyk2 and JAK1, which will prevent the 






Figure 6. Blocking innate immune signaling 
WNV has evolved several different ways to block the innate intracellular immune 
response.  Both WNV E and NS1 may be able to block TLR3 signaling, KUNV 
NS2A can inhibit IFN-β transcription, WNV NS5 was reported to inhibit Tyk2 
and JAK1 phosphorylation, and WNV NS4B can partially block STAT1 signaling 
while NS2A, NS2B, NS3, NS4A, and NS4B have been shown to inhibit STAT2 





showed that IFN-α signaling and STAT2 nuclear translocation was inhibited by 
WNV NS2A, NS2B, NS3, NS4A, and NS4B, but not NS1 and NS5 [46].  WNV 
NS4B was found to have the ability to partially block STAT1 signaling, which 
induced fewer ISGs [148].  By mutating certain residues within WNV NS4B in a 
subgenomic replicon, the protein’s ability to block IFN signaling was abolished.  
However, WNV generated from infectious clones containing these same 
mutations retained their ability to block the IFN response, suggesting a role for 
structural genes in the inhibition of IFN signaling [150]. 
 
9. Significance of dissertation research 
Very few studies have focused on the initial infection of dermal fibroblasts 
with WNV. Since these cells are part of the initial infection, they may play an 
important role in the early propagation and dissemination of the virus.  Here, I 
examine the host-pathogen interactions between WNV and human dermal 
fibroblasts (HFFs) with both a pathogenic strain (WNV-NY) and a nonpathogenic 
strain (WNV-AUS60).  More specifically, I study the HFF innate intracellular 
immune response to both WNV strains.  I also examine the factors that control 
WNV replication and spread.  While both strains are capable of replicating within 
dermal fibroblasts, WNV-AUS60 replicates to lower levels and spreads less from 
cell to cell in HFFs than WNV-NY.  At the very low multiplicity of infection 
(MOI) of 0.005 and the low MOI of 0.05, both viruses stimulate similar IFN 




infection of HFFs until later times post infection.  Specifically, IFN-β plays a role 
in modulating WNV particle infectivity at late, but not early times post-infection 
in HFFs.  In addition, peak viral titers are lower for WNV-AUS60 compared to 
WNV-NY due to an IFN-independent reduction in viral infectivity and an 
inability to spread beyond the initially infected cells.  These studies indicate that 
dermal fibroblasts are capable of supporting WNV replication; however, the low 
infectivity of particles produced from HFFs late in infection suggests that this cell 
type likely plays a limited role as a viral reservoir in vivo.  The work in this 
dissertation highlights both IFN-dependent and IFN-independent mechanisms that 
can reduce WNV infectivity in dermal fibroblasts, which comprise an initial site 





Chapter 2: Characterization of Factors Reducing West Nile 
virus Infectivity in Human Dermal Fibroblasts 
 
1. Introduction 
West Nile virus (WNV) is a neurotropic Flavivirus that has recently 
emerged as a significant threat to human health.  Prior to the 1990s, most WNV 
infections were asymptomatic or associated with a mild febrile illness known as 
West Nile fever. However, the recent introduction of WNV into naïve populations 
in Europe, Israel, and the Americas has resulted in a marked increase in both the 
number of reported cases and the severity of disease when compared to previous 
outbreaks.  
Based on the phylogenetic analysis of partial genomic sequences of 
structural genes, WNV has been grouped into five lineages and two clades, which 
differ from each other by 20-27% [54, 55].  Most strains reside within the two 
main lineages, designated Lineage 1 and Lineage 2. Lineage 1 strains have been 
isolated from North America, Europe, the Middle East, Africa, Asia and 
Australia.  While Lineage 2 strains were initially confined to sub-Saharan Africa, 
they have recently been detected in eastern and southern Europe as well as South 
Africa [62-64, 66-70].  Experimental infections in rodents and birds demonstrated 
that the virulence and neuroinvasiveness of strains from both Lineage 1 and 2 are 




WNV is primarily maintained in nature in an enzootic transmission cycle 
between avian hosts and mosquito vectors.  Though mosquitos can transmit WNV 
to humans and other mammals, this normally results in a dead-end infection since 
levels of viremia are not sufficient for transmission back to the mosquito vector 
[23].  Transmission of WNV to avian and mammalian hosts occurs when an 
infected mosquito deposits saliva containing high doses of virus into the dermal 
layer of the skin while probing for a blood vessel [89, 91,151-153].  The 
deposited virus is thought to infect local skin cells as well as immune cells that 
are recruited to the inoculation site, such as neutrophils and Langerhans dendritic 
cells [154].  Studies with WNV and dengue virus (DENV) suggest that the 
immune cells promote viral dissemination by transporting the virus to draining 
lymph nodes, where a second round of replication occurs in Langerhans cells [93, 
95, 96, 155, 156].  The amplified virus then enters the circulatory system via the 
efferent lymphatic system and the thoracic duct. The subsequent viremia allows 
WNV to access distal organs, including the spleen, heart, liver, kidneys, and 
brain.  
As one of the first cell types exposed to WNV during a mosquito’s blood 
meal, the nonmigrating cells within the skin may function as an early reservoir for 
WNV infection.  While keratinocytes, the major cell type comprising the 
epidermal layer of the skin, have been shown to support high levels of WNV 
replication [90], primary human dermal fibroblasts are also capable of sustaining 
the replication of WNV and several other Flaviviruses [92].  Because little else is 




skin, we further assessed the ability of WNV to propagate in primary dermal 
fibroblasts.  Specifically, we compared the ability of a pathogenic, WNV-New 
York (WNV-NY) [157], and a nonpathogenic, WNV-Australia (WNV-AUS60) 
[59], Lineage I strain to replicate in these cells. While both strains of WNV 
replicated in dermal fibroblasts, WNV-AUS60 achieved lower overall peak viral 
titers compared to WNV-NY.  By treating HFFs with supernatants from previous 
infections, we determined that a factor secreted from WNV-infected HFFs was 
limiting subsequent WNV infections.  Although IFN was not detected, IFN-
dependent ISGs were induced in WNV-infected HFFs.  Together, this work 
suggests that WNV-infected HFFs secrete very low levels of type-I IFN and these 
cells are highly sensitive to the inhibitory effects of small amounts of IFN. 
 
2. Results and Discussion 
2.1 WNV replication in human dermal fibroblasts 
The replication kinetics of pathogenic (WNV-NY) and nonpathogenic 
(WNV-AUS60) strains of WNV in human dermal foreskin fibroblast cells (HFFs) 
were assessed using a multistep growth curve at an MOI of 0.005.  Both viruses 
replicated within HFFs without obvious induction of cytopathic effects (CPE) 
(data not shown).  WNV-AUS60 reached peak infectious particle production by 
24 h post-infection, while the viral set point of WNV-NY was obtained at 40 h 






Figure 7. WNV replication and spread in HFFs 
HFF cells were infected at an MOI of 0.005 with either WNV-AUS60 or WNV-
NY.  (A) Levels of infectious virus in supernatants collected at 1, 16, 24, 32, 40, 
48, and 72 h post-infection were measured by plaque assay on Vero cells.  Each 
point represents duplicate titers of at least three independent experiments.  
Statistical significance relative to WNV-AUS60 levels at each time point were 
determined by an unpaired t-test where * represents p<0.05, ** represents p<0.01, 
and ***represents p<0.001. (B) Cells were fixed with 3% PFA 24 h post-
infection, permeabilized and labeled with WNV antisera followed by FITC 





 WNV-AUS60 was restricted in its ability to spread from cell to cell within the 
HFF monolayer compared to WNV-NY at 24 h post-infection (Figure 7B). 
Therefore, reduced cell-to-cell spread may contribute to lower peak titers of 
WNV-AUS60 compared to WNV-NY. 
 
2.2 Sequential infection in HFFs limits WNV-NY replication 
We hypothesized that WNV-AUS60-infected HFFs secrete a factor that 
limits the ability of this strain to spread from cell-to-cell.  Since this factor may 
also be able to limit the spread of WNV-NY, we performed sequential infections 
in HFFs (Figure 8A).  Cultures were mock- or WNV-AUS60-infected for 24 h.  
Following these initial infections, the HFFs were mock- or WNV-NY-infected for 
an additional 24 h and analyzed using quantitative reverse transcriptase-PCR 
(qRT-PCR) to determine viral levels (Figure 8 B,C). WNV-AUS60 levels were 
not affected by subsequent WNV-NY infection.  However, WNV-NY replication 
was significantly decreased when HFFs were initially infected with WNV-AUS60 
compared to mock (Figure 8C). Because the cells were infected at an MOI of 
0.005 with each virus, it is not likely that any cells were co-infected.  Therefore, 
WNV-AUS60-infected cells likely secrete a factor to limit further WNV 
infection. 
 
2.3 WNV infections of HFFs are limited by a secreted factor 
To confirm the presence of a secreted factor, supernatants from previous 







Figure 8. WNV infection is limited after sequential infection in HFFs 
(A) A schematic of the sequential infection.  (B, C) HFF cells were mock- or 
WNV-AUS60-infected for 24 h at an MOI of 0.005.  After, cells were mock- or 
WNV-NY-infected at an MOI of 0.005 for 24 h. Total RNA was extracted and 
analyzed by qRT-PCR with primers specific to a portion of the genome encoding 
the envelope of either (B) WNV-AUS60 or (C) WNV-NY. Genome copies per ng 
RNA for each sample were determined by comparing genome copy levels to 
GAPDH levels.  Each point represents triplicate analysis of at least three 




Supernatants from 24 h mock- or WNV-AUS60-infections of HFFs were UV-
treated and virus was inactivated to levels undetectable by plaque assay. HFFs 
were treated with inactivated supernatants prior to infection with WNV-NY 
(Figure 9A).   WNV-NY infectious particle production was lower when HFFs 
were treated with supernatants from WNV-AUS60 infections compared to 
supernatants from mock infections (Figure 9B).  WNV-NY infectious particle 
production was similarly inhibited in HFFs treated with UV-inactivated 
supernatants recovered from WNV-NY-infected cultures (data not shown). The 
inhibitory effect of treatment with supernatants from WNV-AUS60 infections 
suggests that WNV-infected HFFs secrete a factor that limits subsequent WNV 
infections.   
2.4 Characterization of the inhibiting factor(s) secreted by WNV-AUS60-
infected HFFs 
To further characterize the factor(s) secreted by WNV-AUS60-infected 
HFFs, we assessed its effect on other cell lines.  Initial characterization involved 
verifying if the secretion of and response to this factor(s) was cell-type specific.  
To make this determination, A549 (Figure 10A,B,C) and Vero (Figure 10A,D,E) 
cells were first mock- or WNV-AUS60-infected for 24 h.  Subsequently, the 
HFFs were mock-or WNV-NY-infected for 24 h, and then total RNA was 
extracted from the cells using Trizol. The RNA was analyzed with qRT-PCR 
analysis.  Similar to the HFF infections, WNV-AUS60 replication remained the 
same after 48 h in the presence of a secondary 24 h infection with either mock or 






Figure 9. Treatment of HFFs with supernatants from previous WNV HFF 
infections 
(A) Schematic of infection with supernatant treatment.  (B) HFF cells were 
treated with media or supernatants from previous mock- or WNV-AUS60-
infections for 6 h prior to and throughout infections with WNV-NY (MOI of 
0.005) for 24 h. Levels of WNV-NY infectious particle production were 
determined by plaque assay on Vero cells. Each point represents duplicate titers 
of at least three independent experiments. Statistical significance was determined 




Figure 10. WNV infection is not limited after sequential infection in A549 
and Vero cells 
(A) A schematic of the sequential infection.  (B, C) A549 or (D, E) Vero cells 
were mock- or WNV-AUS60-infected at an MOI of 0.005 for 24 h.  After, cells 
were mock- or WNV-NY-infected at an MOI of 0.005 for 24 h and total RNA 
was extracted for qRT-PCR analysis with primers specific to a portion of the 
genome encoding the envelope of either (B, D) WNV-AUS60 or (C, E) 
WNV-NY. Comparing genome copy levels to GAPDH levels, genome copies per 
ng RNA for each sample was determined.  Each point represents triplicate 








 A549 and Vero cells is not altered by a subsequent WNV-NY infection.  Next, 
we focused on the effect of the initial WNV-AUS60 infection on the subsequent 
WNV-NY infection.  Unlike sequential infections in HFFs, WNV-NY replication 
in A549 and Vero cells remained unchanged when HFFs were initially infected 
with WNV-AUS60 compared to mock (Figure 10B,D). Together, these data 
suggest that WNV-AUS60-infected A549 and Vero cells do not produce and/or 
respond to an inhibitory secreted factor comparable to the factor secreted by 
WNV-AUS60-infected HFFs. 
Further characterization involved determining the effect of supernatants 
from WNV-infected HFFs on WNV infection of A549 cells.  Supernatants from 
24 h WNV-AUS60 infections of HFFs were used to treat A549 cells prior to and 
throughout a 24 h WNV-NY infection (Figure 11A).  Unlike HFF infections, 
treatment with supernatants from WNV-AUS60 infections of HFFs had no effect 
on WNV-NY infections of A549 cells (Figure 11B), suggesting that A549 cells 
do not respond to the inhibitory factor present in supernatants recovered from 
WNV-AUS60 infected HFFs. 
To assess some basic biochemical properties of the inhibitory factors 
within the supernatants recovered from WNV infections of HFFs, we evaluated 
their thermal stability.  While incubation at 56°C for 30 min is sufficient to 
inactivate some viruses, WNV supernatants required additional treatment with 
UV-light to decrease levels of virus below detectable limits.  HFFs were exposed 





Figure 11. Treatment of A549 cells with supernatants from previous WNV 
HFF infections 
(A) Schematic of A549 infection with HFF supernatant treatment.  (B) A549 cells 
were exposed to UV-treated media or supernatants recovered from mock or 
WNV-AUS60 HFF infections for 6 h prior to and throughout infections with 
WNV-NY at an MOI of 0.005 for 24 h. Each point represents duplicate titers of at 




WNV-NY (Figure 12A).  Exposure of WNV-AUS60 supernatants to heat 
abolished their inhibitory effects (Figure 12B) compared to supernatants that were 
only exposed to UV-light treatment in Figure 9B.  Therefore, the secreted factor 
produced by WNV-AUS60-infected HFFs is heat-labile.  
An additional biochemical property that we tested was pH stability of the 
factors in the supernatants from WNV-infected HFFs.  Like heat-treatment, acid 
treatment was not sufficient to inactivate WNV.  WNV supernatants required 
additional treatment with UV-light to fully inactivate virus.  HFFs were incubated 
with UV- and acid-treated WNV-AUS60 supernatants prior to and throughout 
infection with WNV-NY (Figure 12C).  Low pH and UV light also abolished the 
inhibitory effects of WNV-AUS60 supernatants (Figure 12C) when compared to 
supernatants that were only exposed to UV light treatment in Figure 9B.  
Therefore, the secreted factor produced by WNV-AUS60-infected HFFs is both 
heat- and acid-labile.  Work by Rentsch and Zimmer showed that IFN-β retained 
its antiviral activity, as measured by bioassay in normal dermal human fibroblasts, 
when heated up to 60°C for 30 min or treated with 0.1 M HCl for 30 min [159]. 
This suggested that the factor secreted by WNV-AUS60-infected HFFs was not 
IFN-β. 
 
2.5 IFNα/β was not detected in supernatants from WNV HFF infections 
To directly assess whether IFN was induced during WNV-infection in 




Figure 12. Treatment of HFFs with heat- and acid-treated supernatants from 
previous WNV HFF infections 
(A) Schematic of infection with heat-inactivated supernatant treatment.  (B) HFF 
cells were treated with supernatants from previous WNV-AUS60 infections, 
mock infections or media before and after infection with WNV-NY. Specifically, 
supernatants from 24 h mock- or WNV-AUS60-infections that were UV-
inactivated then incubated at 56°C for 30 min, were used to treat HFF cells for 6 
hours prior to and throughout infection with WNV-NY at an MOI of 0.005 for 
24 h.  (C) Schematic of infection with acid-treated supernatant treatment.  (D) 
HFF cells were treated with supernatants from previous WNV-AUS60 infections, 
mock infections or media before and after infection with WNV-NY. Specifically, 
supernatants from 24 h mock- or WNV-AUS60-infections that were UV-
inactivated then incubated with 0.1 M HCl for 30 min then neutralized, were used 
to treat HFF cells for 6 hours prior to and throughout infection with WNV-NY at 












bioassay quantified protection from infection with a virus that is highly 
susceptible to type-I IFN treatment, vesicular stomatitis virus (VSV) [160].  For 
the bioassay, A549 cells were pretreated with supernatants from mock, WNV-
AUS60, and WNV-NY HFF infections alongside an IFN standard for 24 h or cells 
were untreated. After a 24 h VSV infection, levels of VSV in supernatants were 
assessed by plaque assay (Figure 13A).  Decreased VSV levels were observed 
when cells were pretreated with an IFN standard as compared to untreated cells.  
Conversely, treatment with supernatants from mock-, WNV-AUS60-, and WNV-
NY-infections of HFFs had no effect on VSV titers (Figure 13B).  This suggests 
that IFN is not present or is below the limit of detection for this assay.   
To assess IFN induction with a more sensitive assay, we analyzed total 
RNA isolated from WNV-infected HFFs using qRT-PCR analysis.  While IFN-β 
transcription was induced in control A549 cells infected with WNV-NY, it was 
not induced in WNV-AUS60- or WNV-NY-infected HFFs (Figure 13C).  
Combined, these data suggest that IFN-β is not present or below detectable limits 
in cells and supernatants from WNV infections of HFFs. 
While it is known that IFN-β signals pathways that lead to the inhibition 
of WNV infection, other cytokines may also play a role in the inhibition of HFF 
infection.  In addition to testing for the presence of type-I IFN, levels of type-III 
IFN, IFN-λ, were also assessed.  IFN-λ is an interferon stimulated gene (ISG) that 




Figure 13. Detection of IFN in supernatants from WNV HFF infections 
(A) Schematic of IFN bioassay on A549 cells. (B) IFN bioassay. Prior to a 24 h 
infection with VSV at an MOI of 1, A549 cells were treated for 24 h with media, 
12.5 IU/ml IFN-β, or UV-inactivated supernatants from 24 h-WNV-AUS60 or 
WNV-NY infections.  VSV titers were determined by plaque assay on Vero cells.  
Each point represents duplicate titers of three independent experiments. Statistical 
significance was determined by an unpaired t-test where *** represents p<0.001.  
(C,D) One-step qRT-PCR analysis. Total RNA was isolated from HFF cells 
infected at an MOI of 0.005 with mock, WNV-AUS60, WNV-NY or A549 
control cells infected at an MOI of 1 with WNV-NY.  RNA from WNV-infected 
cells was analyzed in the presence of SYBR Green with primers specific to 
human (C) IFN-β and GAPDH or (D) IFN-λ and GAPDH then compared to 
values from mock-infected cells. (C,D) Each point represents triplicate analysis of 
at least two independent experiments. Statistical significance was determined by 









antiviral activity against positive-sense ssRNA viruses, like encephalomyocarditis 
virus (EMCV) [161].  A study examining the effects of IFN-λ on WNV infection 
showed that IFN-λ could slightly inhibit the infection of epithelial cells with WN 
virus-like particles, but not virus replication [162].  To assess levels of IFN-λ2/3 
transcription, total RNA from mock-, WNV-AUS60-, and WNV-NY-infected 
cells was analyzed using qRT-PCR.  Like IFN-β levels, IFN- λ2/3 transcription 
could be detected in control A549 cells infected with WNV-NY, but not in WNV-
AUS60- or WNV-NY-infected HFFs (Figure 13D).  This suggests that IFN-λ 
does not contribute to the inhibition of WNV infection in HFFs.  
 
2.6 Characterization of the innate intracellular antiviral effector proteins 
produced during WNV infection 
While IFN was not detected by type-I IFN bioassay in cells and 
supernatants from WNV infection of HFFs at an MOI of 0.005, western blot 
analysis of the intracellular proteins suggests that IFN is secreted by HFFs 
infected with WNV.  By 24 h post-infection with either WNV-AUS60 or WNV-
NY, ISGs, such as Interferon Regulatory Factor-9 (IRF-9), Interferon Stimulated 
Gene 15 (ISG15), Interferon Stimulated Gene 56 (ISG56) and phosphorylated 
Signal Transducer and Activator of Transcription-2 (phospho-STAT-2) can be 
detected by western blot (Figure 14).  Production of ISG15 and ISG56 can be a 
result of either IFN-independent IRF-3 activation or downstream IFN production 






Figure 14. Induction kinetics of antiviral effector proteins resulting from 
WNV-AUS60 and WNV-NY infection of HFFs 
HFF cells were infected at an MOI of 0.005 with either mock, WNV-AUS60, or 
WNV-NY.   Whole-cell lysates were collected at indicated times post infection. 
Levels of WNV, ISG56, ISG15, IRF-9, Phospho-STAT-2, STAT-2, and GAPDH 
were examined by immunoblot.  Images are representative of three independent 
experiments. 




[118,163-167].  Phospho-STAT2 was detected in WNV-infected HFFs, 
suggesting that IFN is being produced at levels that are below the limit of 
detection of several standard IFN quantification assays. 
However, these results do not correspond with the biochemical profile 
previously observed by Rentsch and Zimmer, showing that IFN-α, IFN-β, and 
IFN-λ retained their antiviral activity, as measured by bioassay in normal dermal 
human fibroblasts, when heated up to 60°C for 30 min [158].  They also showed 
that IFN-β and IFN-λ retained their antiviral activity when treated with 0.1 M 
HCl for 30 min [158]. In these experiments, the normal human dermal fibroblasts 
were treated with approximately 10 IU/ml IFN-β. However, we have 
demonstrated that 0.625 IU/ml IFN-β is sufficient to limit VSV infection of 
human dermal fibroblasts [159].  Therefore, low levels of residual activity in the 
heat- and acid-treated IFN may be sufficient to inhibit viral infection in dermal 
fibroblasts.  
We hypothesized that heat and acid treatment may abolish the antiviral 
activity of samples containing IFN at the threshold level of biological activity. 
Treatment of HFFs with 2 and 10 IU/ml IFN-β reduced VSV titers by 2 and 2.5 
logs, respectively, when compared to an untreated control (Figure 15A, B).  When 
testing the effects of heat and low pH on WNV supernatants, additional treatment 
with UV-light was required to completely inactivate all virus present (Figure 12). 
Following exposure to UV light, treatment with 2 IU/ml IFN-β decreased VSV 
titers by 1 log and 10 IU/ml IFN-β decreased VSV titers by 3 logs, as compared 





Figure 15. Effect of heat and acid treatment on low levels of IFN-β 
(A) HFF cells were incubated with untreated or heat-treated IFN-β before and 
after infection with VSV. Specifically, 2 or 10 IU/ml IFN-β was incubated at 
56°C for 30 min, then used to treat HFF cells for 6 h prior to and throughout the 
24 h infection with VSV at an MOI of 1. (B) HFF cells were exposed to untreated 
or acid-treated IFN-β before and after infection with VSV. Specifically, 2 or 10 
IU/ml IFN-β was incubated with 0.1 M HCl for 30 min, neutralized, and then 
used to treat HFF cells for 6 hours prior to and throughout the 24 h infection with 
VSV at an MOI of 1. (C) HFF cells were treated with UV-treated or heat- and 
UV-treated IFN-β before and after infection with VSV. Specifically, 2 or 10 
IU/ml IFN-β was UV-treated then incubated at 56°C for 30 min and used to treat 
HFF cells for 6 hours prior to and throughout the 24 h infection with VSV at an 
MOI of 1.  (D) HFF cells were exposed to UV-treated or acid- and UV-treated 
IFN-β before and after infection with VSV. Specifically, 2 or 10 IU/ml IFN-β was 
UV-treated prior to incubating with 0.1 M HCl for 30 min, neutralized, and then 
used to treat HFF cells for 6 hours prior to and throughout the 24 h infection with 
VSV at an MOI of 1. Each point represents duplicate titers of at least three 
independent experiments.  Statistical significance was determined by an unpaired 
t-test. Asterisks indicate differences that are statistically significant (* p<0.05, ** 










To compare the effects of heat and acid treatment on low levels of IFN to 
the previous biochemical treatments of supernatants from WNV-infected HFFs, 
IFN-β controls were also treated with heat or acid.  These heat- and acid-treated 
IFN controls were used to treat cells pre- and post-infection with VSV.  Upon 
heat-treatment, the inhibitory effect of 2 IU/ml IFN-β was completely abrogated 
while 10 IU/ml retained a slight effect (Figure 15A).  With heat- and UV-
treatment, IFN at either concentration had virtually no effect on VSV titers 
(Figure 15C).  Therefore, with and without UV-treatment, heat-treatment of low 
levels of IFN-β abolishes its biological activity.   
When 2 IU/ml IFN-β was exposed to low pH, its effect on VSV infection 
was slightly inhibited, but 10 IU/ml IFN-β remained unchanged (Figure 15B).  
With both UV- and acid- treatment, the inhibitory effect of IFN-β on VSV titers 
only decreased slightly (Figure 15D).  Therefore, UV-treatment inhibits the 
effects of low levels of IFN-β, but higher levels retain their inhibitory effect on 
VSV infection.  However, acid-treatment of IFN-β in the presence and absence of 
UV-light treatment slightly dampens its ability to inhibit VSV infections.   
Based on a previously published analysis of the biochemical properties of 
type-I IFN, IFN in supernatants from WNV infections of HFF did not appear to 
be responsible for controlling the inhibition of subsequent WNV infection.  
However, our analysis indicated that low levels of IFN might be present. These 
low levels may have been sufficient to inhibit WNV infection, but the biological 






Since little is known about WNV infection of dermal cells and mosquito-
borne viruses are known to infect both epidermal and dermal cells upon 
mammalian infection [90, 168], we further assessed the ability of WNV to 
propagate in primary dermal fibroblasts.  Specifically, we compared the ability of 
a pathogenic, WNV-New York (WNV-NY) [157], and a nonpathogenic, WNV-
Australia (WNV-AUS60) [59], Lineage I strain to replicate in these cells. Peak 
titers of WNV-AUS60 were lower than those of WNV-NY, which may be due to 
a lack of cell-to-cell spread.  Since treatment with UV-inactivated supernatants 
from WNV infections of HFFs limits subsequent infections, a secreted factor is 
likely responsible for this inhibition.  
To quantify levels of type-I IFN in supernatants from WNV infections of 
HFFs, we initially utilized an IFN bioassay on A549 cells.  At the MOI of 0.005, 
the levels of IFN were below the limit of detection of the IFN bioassay on A549 
cells, 2 IU/ml.  For a more sensitive assay, we assessed levels of IFN-β transcripts 
in WNV-infected HFFs via qRT-PCR.  Further analysis of WNV-infected cells by 
qRT-PCR analysis demonstrated that IFN-β, as well as IFN-λ mRNA levels were 
below the limit of detection of this assay.   
To further characterize the factor, we assessed its effect on other cell 
types, its thermal stability and its acid tolerance.  When supernatants containing 
the factor were used to treat WNV-infected A549 cells, the treatment had no 
effect on the infection.  This suggested that the concentrations of the factor in the 




Following incubation at a high temperature or a low pH, the inhibitory effect of 
the supernatant from WNV infections was abolished.  Although the heat- and 
acid-sensitivity profile suggested that the factor was not IFN, the detection of 
phospho-STAT2 by immunoblot suggests that IFN is being produced. However, 
the levels are below the limit of detection of standard assays.  Previous studies 
focusing on 24 to 48 h infections of human foreskin fibroblasts with dengue virus 
at an MOI of 10 led to the production of IFN-β, which protected uninfected cells 
from dengue virus infection [92].  These observations suggest that infection at a 
higher MOI will lead to the secretion of IFN at detectable levels.  The next 






Chapter 3: IFN-Dependent and -Independent Reduction in 
West Nile virus Infectivity in Human Dermal Fibroblasts 
 
1. Introduction 
Following the work in the previous chapter, a new stock of WNV-AUS60 
was generated that contained ten times more infectious particles.  The highest 
possible multiplicity of infection (MOI) for WNV-AUS60 infection of HFFs with 
the previous stock was 0.005, but the new stock allowed for infection at a higher 
MOI of 0.05.  Even with the higher multiplicity of infection, WNV-AUS60 
achieved lower overall peak viral titers compared to WNV-NY.  At this higher 
MOI, IFN-β could be detected in supernatants from WNV-AUS60 and WNV-NY 
infections by type-I IFN bioassay.  While IFN-β affected replication and particle 
infectivity of both strains late in infection, it had no effect at early times post-
infection.  Moreover, IFN-β neutralization increased particle infectivity for both 
strains late in infection; however a significant difference in WNV-AUS60 and 





2. Results and Discussion 
2.1 WNV replication in human dermal fibroblasts 
To expand upon the work in the previous chapter, we compared the 
replication kinetics of insect cell-passaged WNV-NY and WNV-AUS60 in 
human dermal foreskin fibroblasts (HFFs) at a higher MOI of 0.05 PFU/cell 
(Figure 16A).  Like the very low MOI of 0.005, pathogenic, WNV-NY, and the 
nonpathogenic, WNV-AUS60, strains replicated within HFFs without obvious 
induction of cytopathic effects (CPE) (data not shown).  At this higher MOI, both 
strains reached peak infectious particle production between 20 and 24 h post-
infection (Figure 16A).  However, peak viral titers of WNV-AUS60 were 
approximately one log lower than WNV-NY.  Additionally, quantitative RT-PCR 
(qRT-PCR) analysis revealed that the kinetics of WNV-NY and WNV-AUS60 
genome replication occurred at similar rates (Figure 16B). Peak levels of viral 
genome accumulation were detected at 24 h post-infection and lower levels of 
viral genomic RNA were detected at all times in WNV-AUS60-infected cells 
compared to WNV-NY-infected cells.  Therefore, although both strains were 
capable of establishing an infection within HFFs, the nonpathogenic strain, WNV-
AUS60, never reached levels of replication as high as the pathogenic strain, 
WNV-NY. 
We hypothesized that WNV-AUS60 multiplication in HFFs is reduced 
compared to that of WNV-NY due to a defect in cell-to-cell spread.  Therefore, 
we examined viral protein expression in infected cells by an immunofluorescence 




Figure 16. WNV replication in HFFs 
HFF cells were infected (MOI=0.05) with WNV-NY or WNV-AUS60. (A) WNV 
infectious particles production in HFFs. Culture supernatants were recovered at 
the indicated times and titered by plaque assay on Vero cells. Values represent the 
average number of plaque forming units (PFU) per mL (+/- standard error) from 
three independent experiments. (B) RNA synthesis of WNV-NY and WNV-
AUS60 in HFFs. Total RNA was extracted from cells at the indicated times and 
viral RNA levels were assessed by qRT-PCR. Relative WNV genome copies were 
calculated as a change in WNV genome copies per ng of RNA from 1 h post-
infection.  Values represent the average (+/- standard error) of at least three 
independent experiments. (C) Examination of viral protein expression by IFA. 
HFFs were fixed with 3% PFA at 24 h post-infection, permeabilized, dyed with 
Hoescht stain (blue), and probed with WNV hyperimmune ascitic fluid and goat 
anti-mouse IgG 549 nm-Dylight conjugated secondary antibody (red). Images are 
representative of at least three independent experiments. (D) WNV spread in 
HFFs. The number of infected cells within the monolayer was determined by flow 
cytometry. Monolayers were trypsinized at the indicated times, fixed with 3% 
PFA and probed with WNV hyperimmnue serum. Values represent the average 
number (+/- standard error) of WNV-positive cells per 105 cells from three 
independent experiments. Statistical significance was determined by an unpaired 
t-test. Asterisks indicate differences that are statistically significant (*p<0.05, 









infected cultures after 24 h, WNV protein expression was primarily restricted to 
single cells within WNV-AUS60-infected cultures (Figure 16C).  Like infection 
at the very low MOI of 0.005, the detection of unicellular foci with infection at 
the low MOI of 0.05 suggests that WNV-AUS60 is restricted in its ability to 
spread from cell to cell within the HFF monolayer compared to WNV-NY. To 
confirm this result, we quantitated the number of infected HFFs over the course of 
infection using flow cytometry (Figure 16D). Similar levels of WNV-positive 
cells were detected at 12 h post-infection in WNV-NY- and WNV-AUS60-
infected cultures, indicating that both viruses initially established comparable 
levels of infection within the HFF monolayer.  However, the number of WNV-
NY-positive cells increased between 12 and 24 h post-infection, whereas the 
number of WNV-AUS60-positive cells remained unchanged.  Thus, WNV-
AUS60 is impaired in its ability to spread beyond the initially infected cells. 
 
2.2 IFN response to WNV in HFFs 
The restriction of viral spread within HFF cultures was suggestive of 
paracrine protection by type-I IFN since previous work has shown that WNV 
infection is controlled by IFN-α/β in other in vivo and in vitro models [169-171].  
Therefore, we measured the levels of type-I IFNs in supernatants recovered from 
WNV-infected HFFs using a bioassay on A549 cells. While approximately 160 
IU/ml of IFN was detected in supernatants recovered from WNV-NY-infected 
cells at 48 h post-infection, IFN was not detected at 24 h post-infection (data not 




was not detected in supernatants recovered from mock- or WNV-AUS60-infected 
cells at either 24 or 48 h post-infection (data not shown).  Consistent with 
infections at the very low MOI of 0.005, ISGs, such as Interferon Regulatory 
Factor-9 (IRF-9), Interferon Stimulated Gene 15 (ISG15), Interferon Stimulated 
Gene 56 (ISG56), phosphorylated Signal Transducer and Activator of 
Transcription-1 (phospho-STAT-1), and phospho-STAT2 were detected by 
western blot from cultures infected with WNV-NY- and WNV-AUS60 at the 
MOI of 0.05 (Figure 17A). Comparable to western blot analysis of lysates from 
cells infected at the MOI of 0.005, both WNV-NY and WNV-AUS60 infections 
at the MOI of 0.05 induced the expression of a panel of interferon-stimulated 
genes (ISGs) with similar amplitude and kinetics.  Combined, these data suggest 
that both strains induced IFN responses in HFFs as early as 24 h post-infection, 
though the level of IFN expression was below the detection limit of 2 IU/ml of a 
standard bioassay using A549 cells. Therefore, we assessed whether HFFs were 
sensitive to low levels of IFN.  HFFs were treated with 0.625 to 2.5 IU/ml of 
IFN-β and infected with vesicular stomatitis virus (VSV), a virus that is highly 
sensitive to the antiviral effects of IFN (Figure 17B). VSV replication in HFFs 
was suppressed in a dose-dependent manner, indicating that levels as low as 0.625 
IU/ml of IFN-β are capable of inducing an antiviral state within this cell line.  
Based on these results, we reassessed IFN levels in supernatants from 




Figure 17. Antiviral response to WNV-AUS60 and WNV-NY in HFFs 
(A) Steady state protein levels of WNV, ISG56, ISG15, Phospho-STAT-2, STAT-
2, Phospho-STAT-1, STAT-1, IRF-9, and GAPDH in mock-, WNV-AUS60- or 
WNV-NY-infected (MOI=0.05) HFF cells. Extracts prepared at the indicated 
times post-infection were examined by immunoblot. A representative example 
from three independent experiments is shown. (B) Sensitivity of HFFs to IFN. 
HFF cells were treated with 0, 0.625, 1.25, or 2.5 IU/ml IFN-β for 24 h prior to 
infection with VSV (MOI=1). Supernatants were collected at 24 h post-infection 
and VSV titers were determined by plaque assay on Vero cells. Values represent 
the average number of plaque forming units (PFU) per mL (+/- standard error) 
from at least three independent experiments. Statistical significance was 
determined by an unpaired t-test. Asterisks indicate differences that are 
statistically significant (*** p< 0.001). (C) Determination of the WNV-induced 
IFN levels using a VSV-based bioassay on HFFs. HFF cells were treated with 
specified supernatants for 24 h prior to infection with VSV (MOI=1). 
Supernatants were collected at 24 h post-infection and VSV titers were 
determined by plaque assay on Vero cells. Values represent the level of type-I 
IFN (IU/mL) (+/- standard error) from three independent experiments. The dashed 











more sensitive assay, approximately 2 IU/ml of IFN were detected in supernatants 
recovered from WNV-NY- and WNV-AUS60-infected cells at 24 h post-infection 
(Figure 17C).  Thus, both viruses induce the expression of low levels of IFN at 
early times post-infection.  While higher levels of secreted IFN were detected in 
supernatants of WNV-NY-infected HFFs at 48 h post-infection, this was likely 
due to a greater number of infected cells secreting IFN and not higher levels of 
IFN secreted from each infected cell. 
While it is known that IFN-β signals pathways that lead to the inhibition 
of WNV infection, other cytokines may also play a role in the inhibition of HFF 
infections.  In addition to testing for the presence of type-I IFN, levels of type-III 
IFN, IFN-λ, were also assessed.  IFN-λ is an interferon stimulated gene (ISG) that 
has been shown to have antiviral activity during infection with positive-sense 
ssRNA viruses, like encephalomyocarditis virus (EMCV) [161].  A cytokine that 
has been shown to work in concert with IFN-β is TNF. Treatment of fibroblasts 
with TNF in addition to IFN-β has shown to induce a distinct antiviral state[172]. 
Another important aspect of the antiviral response is the attraction of 
leukocytes.  CCL2 (monocyte chemoattractant protein-1 or MCP-1), CCL5 
(regulated on activation, normal T cell expressed and secreted or RANTES), and 
CXCL12 (stromal cell derived factor or SDF-1α) are chemokines that are known 
to recruit leukocytes.  Previous work with human cytomegalovirus (hCMV) has 
shown that CCL2 expression is modulated during virus replication [173].  Studies 
focusing on respiratory syncytial virus (RSV) have shown that the chemokine 




175].  Additionally, upon infection with herpes simplex virus (HSV), fibroblasts 
were shown to secrete CCL5 [176].  CXCL12 is a chemokine secreted from 
stromal cells, like fibroblasts, which has been shown to activate the JAK/STAT 
pathway [177]. 
Since other cytokines and chemokines such as IFN-λ, CXCL12, TNF-α, 
and CCL5 have been previously shown to activate antiviral pathways or have a 
direct inhibitory effect on viral infection [161, 162, 172-176], we measured their 
levels in supernatants and cells by qRT-PCR and ELISA (Figure 18).  Production 
of IFN-λ2/3, CXCL12, TNF-α, and CCL2 were not upregulated with WNV 
infection.  Like IFN, CCL5 levels increased with WNV-AUS60 infection and 
further increased with WNV-NY infection, which correspond with increased cell-
to-cell spread. 
To confirm that the low levels of IFN produced in response to WNV 
infection were sufficient to suppress viral replication, we measured WNV-NY 
infectious particle production in HFFs treated with UV-inactivated supernatants 
recovered from mock- or WNV-AUS60-infected cultures.  Compared to cultures 
treated with mock supernatants, WNV-NY titers were only reduced by one log 
when treated with supernatants from WNV-AUS60 infections at the MOI of 0.005 
(Figure 9) and titers were reduced by approximately two logs in cultures treated 
with WNV-AUS60 supernatants from the MOI of 0.05 (Figure 19A).  In control 
cells treated with 25 IU/ml of IFN-β, WNV-NY titers were reduced by 3 logs.  To 




Figure 18. Detection of cytokines in WNV-infected HFFs 
One-step qRT-PCR analysis of total RNA isolated from mock-, WNV-AUS60-, 
or WNV-NY-infected HFF cells (MOI of 0.05).  RNA from mock- and WNV-
infected cells was analyzed in the presence of SYBR Green with primers specific 
to (A) human IFN-λ2/3 and GAPDH or (B) CXCL12 and GAPDH then compared 
to values from mock-infected cells.  (C,D,E) HFFs were infected at an MOI of 
0.05 with mock, WNV-AUS60 or WNV-NY and supernatants were removed and 
UV-treated at 24 or 48 h post-infection.  Levels of (C) TNF-α, (D) CCL2, and (E) 
CCL5 in collected supernatants were measured by ELISA.  Dashed line represents 










Figure 19. Inhibitory capacity of UV-inactivated supernatants recovered 
from WNV-AUS60-infected HFFs 
(A) HFFs were pretreated with UV-inactivated supernatants recovered from 
mock- or WNV-AUS60-infected cells or 25 IU/ml IFN-β for 6 h prior to and 
throughout the 24 h infection with WNV-NY (MOI=0.05).  Viral titers were 
determined by plaque assay on Vero cells. Values represent the average number 
of plaque forming units (PFU) per mL (+/- standard error) from three independent 
experiments. (B) Schematic of pre- and post-treatment of cells with UV-
inactivated supernatants in the presence or absence of neutralizing antibodies to 
IFN-α or IFN-β.  (C and D)  Effects of neutralizing antibodies or specified 
isotype controls to (C) IFN-α or (D) IFN-β on the inhibitory capacity of UV-
inactivated supernatants recovered from WNV-AUS60-infected HFFs. Values 
represent the average number of plaque forming units (PFU) per mL (+/- standard 
error) from three independent experiments. Statistical significance was 
determined by an unpaired t-test. Asterisks indicate differences that are 










the UV-inactivated supernatants were incubated with neutralizing antibodies or 
isotype controls to IFN-α or IFN-β prior to being used to treat HFFs (Figure 
19B). While neutralization of IFN-α had no effect (Figure 19C), addition of 
IFN-β neutralizing antibodies abrogated the inhibitory effect of the WNV-AUS60 
supernatants and restored WNV-NY titers to levels equivalent to those observed 
in control cells treated with mock supernatants (Figure 19D).  Thus, the inhibitory 
effect of the culture supernatant was due to low levels of secreted IFN-β. 
 
2.3 IFN suppresses WNV infectious particle production at late times post-
infection 
To directly assess the effect of IFN on WNV replication, we examined 
infectious virus particle production in the presence and absence of neutralizing 
antibodies to IFN-α or IFN-β.  As expected, neutralization of IFN-α had no effect 
on infectious virus production, indicating that IFN-α does not play a role in 
controlling WNV replication in fibroblasts (Figure 20A).  Likewise, infectious 
particle production was unchanged for both WNV-NY and WNV-AUS60 at 24 h 
post-infection in the presence of neutralizing antibodies to IFN-β and their isotype 
controls.  However, neutralization of IFN-β significantly increased WNV-AUS60 
and WNV-NY titers at 48 h post-infection, though WNV-AUS60 titers remained 
approximately one log lower than WNV-NY (Figure 20B).  Thus, IFN-β appears 
to play a role in controlling WNV infectious particle production at late, but not 






Figure 20. WNV replication in the presence and absence of neutralizing 
antibodies to IFN-α or IFN-β 
HFF cells were infected with WNV-NY or WNV-AUS60 (MOI=0.05) and the 
inoculum was removed after 1 h and replaced with complete DMEM containing 
specified isotype control antisera or neutralizing antibodies to (A) IFN-α or (B) 
IFN-β. Culture supernatants were recovered at the indicated times post-infection 
and viral titers were determined by plaque assay on Vero cells.  Values represent 
the average number of PFU per mL (+/- standard error) from three independent 
experiments. An unpaired t-test was performed to determine significance.  




between WNV-AUS60 and WNV-NY viral set points is regulated by an IFN-
independent mechanism. 
 
2.4 WNV strain variation in particle infectivity during HFF infection 
Key steps in the viral life cycle leading up to infectious particle production 
include translation and replication of the viral genome, assembly of the virus 
particle at the ER membrane, transport of virus particles through the secretory 
pathway, and finally virus release.  To assess whether the lower viral set point for 
WNV-AUS60 was due to impairment at or before the stage of viral assembly, we 
first assessed the WNV-AUS60 stock for the presence of defective interfering 
(DI) particles.  DI particles have been previously shown to inhibit infection with 
WNV [178, 179].  Using a yield reduction assay (YRA) as previously described 
by Barrett et al., we were able to measure levels of DI virus [180].  Briefly, the 
assay measures the ability of a virus to cause a reduction in the yield of infectious 
(or standard) virus when cells are co-infected with both standard and DI viruses.  
With WNV-NY as the standard virus and WNV-AUS60 as the presumed DI 
virus, WNV-NY titers were not reduced in the presence and absence of various 
concentrations of the WNV-AUS60 viral stock (Figure 21A).  This suggests that 
the stock of WNV-AUS60 does not contain inhibitory DI particles, so the reduced 
infectivity of WNV-AUS60 was not due to the generation of defective interfering 
(DI) particles. 
While DI particles were not detected in the WNV-AUS60 stock, we 




Figure 21. Infectivity of WNV particles produced in HFFs 
(A) YRA to detect DI particles in WNV-AUS60 viral stock. A549 cells were 
infected with standard virus, WNV-NY, at and MOI of 5 and WNV-AUS60 at 
increasing MOIs.  Culture supernatants were recovered at 48 h post-infection and 
titered by plaque assay on Vero cells. Values represent the average number of 
plaque forming units (PFU) per ml (+/- standard error) from two independent 
experiments.  (B,C,D) HFF cells were infected at an MOI of 0.05 with WNV-NY 
or WNV-AUS60. (B) Total viral particle production at 24 and 48 h post-infection 
was determined using a flow cytometry-based virus counter. Values represent the 
average number of particles per mL (+/- standard error) from three independent 
experiments. (C, D) WNV infectivity in the presence and absence of specified 
isotype control or neutralizing antibodies to IFN-β at (C) 24 and (D) 48 h post-
infection. The concentration of total virus particles and infectious particles was 
determined using a flow cytometry-based virus counter and plaque assays on 
Vero cells, respectively. (B,C,D) Values represent the average Particle to PFU 
ratio of three independent experiments. Statistical significance was determined by 
an unpaired t-test. Asterisks indicate differences that are statistically significant 









production.  To compare WNV-NY and WNV-AUS60 total virus particle 
production, we used a virus counter.  The virus counter utilizes two dyes in a flow 
cytometry-based system that simultaneously detects nucleic acid and protein, 
thereby excluding empty particles and cellular debris from the analysis.  Similar 
levels of total viral particles were detected for WNV-NY and WNV-AUS60 at 24 
and 48 h post-infection (Figure 21B), suggesting that WNV-AUS60 and 
WNV-NY replicate and assemble at similar rates and to equivalent levels within 
HFFs. Using the physical counts of total virus particles obtained from the virus 
counter and the biological counts determined by plaque assay, we determined the 
particle to PFU ratio for WNV-NY and WNV-AUS60 at 24 and 48 h post-
infection (Figure 21C, D). Based on these calculations, the infectivity of 
WNV-AUS60 particles was significantly reduced at both time points compared to 
WNV-NY. These data suggest that the lower viral set point for WNV-AUS60 was 
due, in part, to WNV-AUS60 particles being less infectious than WNV-NY 
particles.  
In studies utilizing several different viruses, infected cells treated with IFN 
produced viral particles with lower infectivity compared to untreated control cells 
[181-186].  To assess whether IFN plays a similar role in reducing WNV 
infectivity, we examined the effect of IFN-β neutralizing antibodies on the 
particle to PFU ratios of WNV-NY and WNV-AUS60. Although neutralization of 
IFN-β had no effect on total particle production (data not shown), the particle to 
PFU ratios for both WNV-NY and WNV-AUS60 were substantially reduced at 




in modulating infectivity of WNV particles late in the course of infection. In 
contrast, neutralization of IFN-β had no effect on WNV particle to PFU ratios at 
24 h post-infection (Figure 21C), which is consistent with our previous data 
demonstrating that IFN does not regulate viral titers at this time point. Therefore, 
the higher level of defective particle production observed for WNV-AUS60 at 
24 h post-infection was independent of IFN-β and therefore, due to a strain-
specific defect in infectious particle production. 
 
3. Conclusions 
Here we demonstrate that both nonpathogenic and pathogenic strains of 
WNV are capable of establishing an infection within dermal fibroblasts. However, 
a strain-specific defect in infectious particle production limits the ability of WNV-
AUS60 to disseminate from the initially infected cells, resulting in a lower viral 
set point compared to WNV-NY.  The defect in WNV-AUS60 infectious particle 
production was not specific to human dermal fibroblasts. WNV-AUS60 exhibited 
both a smaller plaque phenotype and reduced titers compared to WNV-NY on 
Vero cells (data not shown).  It is unclear why WNV-AUS60 particles are less 
infectious than those of WNV-NY. 
One possible explanation for limited spread is decreased WNV-AUS60 
replication. If its RNA dependent RNA polymerase (RdRp) has an increased error 
rate, this could push this strain over the error threshold, thus, resulting in an 
increased production of defective particles. A recent study demonstrated that 




compared to wild-type [187].  Alternatively, the lower infectivity of WNV-AUS60 
particles may be due to a reduced capacity to undergo maturation. Flavivirus 
particles secreted from the infected cell are a combination of mature, partially 
mature and immature virions. Recent reports have demonstrated that partially 
mature viral particles are still capable of infecting cells, however, immature 
Flavivirus particles are noninfectious due to an inability to efficiently bind to the 
target cell [24, 188, 189]. Therefore, an increase in the percentage of immature 
particles released from the infected cell would result in decreased infectivity of 
WNV-AUS60 particles.  
We also demonstrated that WNV replication is restricted late in infection 
through an IFN-β-mediated reduction in viral infectivity. Conceivably, this 
reduction in viral infectivity may limit the ability of the dermal layer to serve as a 
productive reservoir for WNV infection. Moreover, the higher level of defective 
particles that are produced late in infection may help to stimulate the adaptive 
immune response to WNV. Since the infectivity of WNV-AUS60 is inherently 
lower than WNV-NY, the IFN-dependent decrease in infectious particle 
production may have a greater impact on the ability of this strain to disseminate 






Chapter 4: Discussion 
 
The public health threat of WNV stems from its recent introduction into 
the Americas, which has resulted in an increase of infections associated with 
neurological disease [19].  Arthropod-borne transmission of the virus occurs when 
an infected mosquito is in search of a blood meal and deposits saliva containing 
high levels of virus into the dermal layer of skin.  Upon initial infection, viral 
replication occurs in cells within the dermal and epidermal layers of skin.  
Utilizing both a pathogenic strain (WNV-NY) and a nonpathogenic strain (WNV-
AUS60), I was able to examine the replication and spread of WNV as well the 
IFN response to WNV infection in human dermal fibroblasts (HFFs). 
 
1. WNV replication and spread in HFFs 
While both strains are capable of replicating within dermal fibroblasts, 
WNV-AUS60 replicates to lower levels and spreads less from cell to cell in HFFs 
than WNV-NY.  At the very low MOI of 0.005, WNV-AUS60 reached peak 
infectious particle production by 24 h post-infection, while the viral set point of 
WNV-NY was obtained at 40 h post-infection (Figure 7A).  WNV-NY viral 
spread was evident at 24 h post-infection by IFA (Figure 7B) and the continued 
increase in viral titers suggests that the virus underwent a second round of 
replication and spread between 24 and 40 h post-infection.  When ten times more 




infectious particle production between 20 and 24 h post-infection (Figure 16A).  
Increasing the concentration of virus within the inoculum eliminated the second 
round of replication and spread after 24 h post-infection (Figure 16A,D). 
Examining viral set points of each strain at the two MOIs, WNV-NY 
reaches 1x106 PFU/ml at the MOI of 0.005 and 1x107 PFU/ml at MOI of 0.05.  
WNV-AUS60 peaks at 1x105 PFU/ml at the MOI of 0.005 and 5x105 PFU/ml at 
the MOI of 0.05.  With both strains, peak viral levels were higher when cultures 
were inoculated at the slightly higher MOI.  This suggests that reaching a viral set 
point is dependent on the number of initially infected cells.  Since WNV-NY is 
known to initially evade the host antiviral response [138-140], there is only a 
window of approximately 12 to 16 h for the virus to replicate without cellular 
detection.  By inoculating cells with more virus, higher titers can be observed 
since an antiviral state will be triggered at the same time post-infection regardless 
of the initial MOI. 
At the MOI of 0.005 or 0.05, WNV-AUS60 and WNV-NY infections both 
induced the production of innate antiviral effector proteins with similar kinetics 
and amplitude.  Between 16 and 24 h post-infection, ISG15, ISG56, IRF-9, and 
phospho-STAT2 were detected in WNV-infected HFFs (Figure 14,16).  
Production of ISG15 and ISG56 can be a result of either IRF-3 activation or 
downstream IFN signaling [137].  IRF-9 (ISGF3 gamma) can be induced 
following viral infection [126] and also complexes with the STAT1-STAT2 
heterodimer to initiate transcription of various IFN-stimulated genes [163].  When 




and JAK, which are associated with the receptors.  Downstream signaling leads to 
the dimerization and phosphorylation  of STAT1 and STAT2 [118].  Since the 
IFN-dependent production of phosho-STAT2 [163-167]is detected in WNV-
AUS60- and WNV-NY-infected cells at similar times post-infection, this suggests 
that WNV-AUS60 and WNV-NY-infected HFFs secrete IFN with similar 
kinetics. 
 
2. Detection of IFN in WNV-infected HFFs 
Using a standard type-I IFN bioassay on A549 cells, IFN was not detected 
in supernatants from 24 h mock, WNV-AUS60, or WNV-NY infections 
(MOI=0.005) of HFFs (Figure 13B).  At the MOI of 0.05, IFN was not detected in 
24 h mock, WNV-AUS60, or WNV-NY supernatants or 48 h mock or WNV-
AUS60 infections (data not shown).  IFN was only detected in HFFs infected with 
WNV-NY for 48 h.  Because immunoblot analysis indicated that IFN was 
signaling activation of the JAK/STAT pathway by 24 h post-infection in WNV-
AUS60- and WNV-NY-infected (MOI of 0.005 or 0.05) cultures, we assessed the 
sensitivity of a HFF bioassay.  HFFs were sensitive to levels as low as 0.625 
IU/ml of IFN-β, while inhibition of infection in A549 cells required a minimum 
of 2 IU/ml IFN.  The high sensitivity of HFFs to IFN allowed for the detection of 
IFN in 24 and 48 h supernatants from WNV-AUS60- and WNV-NY-infected 
cells (MOI=0.05).  Additionally, the increased sensitivity of HFFs to IFN explains 
why WNV-infection supernatants (MOI=0.005) inhibited subsequent HFF, but 




While the secretion of IFN-β can be detected following WNV infection of 
cultured human dermal fibroblasts after 24 h, other types of cells may affect the 
local IFN response within the dermis of a mammal.  In addition to fibroblasts, the 
dermal layer of skin also contains mast cells, adipocytes, and immune cells [190].  
These other cells in the dermis have their own distinct sets of PRRs that can 
recognize a variety of PAMPS to trigger host defense mechanisms.  Future work 
could assess local IFN levels within the dermis of a mouse following intradermal 
WNV inoculation. 
Since in vivo IFN levels would likely be low in dermal cells, it would be 
necessary to assess the sensitivity of dermal cells to treatment with IFN.  
Treatment of cultured human dermal fibroblasts with IFN inhibits WNV 
infection, but this effect may be altered in the dermis of a mammal.  IFN could be 
injected at the site of inoculation before and after intradermal inoculation of 
WNV.  If IFN treatment at the in vivo site of inoculation inhibits WNV infection, 
further studies focusing on local IFN treatment could be pursued. 
There is currently no approved method of treatment or prevention of 
Flaviviruses, including WNV, infection in humans.  Standard treatment for 
persistent Flaviviral infection, such a chronic hepatitis C virus, utilizes pegylated 
IFN-α and ribavirin, but this is often associated with adverse side effects and a 
slow virologic response [191, 192].  IFN-α stimulates the JAK/STAT pathway to 
induce ISGs that can have direct antiviral effects or induce an immune response 
[193, 194].  Ribavirin is a nucleotide analog that incorporates ribavirin 




increase the error frequency of genomic RNA in viruses such as HCV and 
poliovirus because it can bind to both uracil and cytosine [195-197].  While 
ribavirin decreased levels of some viral infections, WNV-infected patients treated 
with ribavirin during an outbreak in Israel exhibited increased disease [198].  A 
later study of WNV-infected hamsters demonstrated that treatment with ribavirin 
increased their death rate [199].  Utilizing a similar antiviral mechanism as 
ribavirin, an adenosine nucleoside inhibitor of DENV was developed more 
recently that reduces infection levels, but has significant adverse side effects [200, 
201].  By studying WNV replication and the effects of type-I IFN on infection, we 
can more thoroughly understand the effects of IFN treatment and improve 
antiviral therapies. 
 
3. IFN-dependent and -independent modulation of WNV particle infectivity 
At the higher MOI of 0.05, IFN-β can be detected at 24 h post-infection, 
but does not limit WNV infection of HFFs until later times post infection.  If the 
reduction in WNV levels at early times post infection is not due to a secreted 
factor, it may be tied to the replication of each virus.  While qRT-PCR analysis 
showed that WNV-AUS60 and WNV-NY had similar rates of replication, it only 
measured the transcription of a small amplicon near the 5’ end of the genome.  
The transcription of this portion of the envelope gene may be replicated at similar 
rates, but the WNV-AUS60 RdRp may have low processivity.  Reports of other 
Flaviviruses show various levels of processivity [52, 202, 203].  Purified NS5, 




low processivity, while a KUNV NS5 RdRp lacked premature termination [52].  
To assess processivity, amplification of a segment in the 3’ NTR could be 
compared to an envelope amplicon of each strain.  
Similar replication rates of WNV-AUS60 and WNV-NY as measured by 
qRT-PCR analysis do not detect mutations within the genome.  The lower 
infectivity of the WNV-AUS60 particles may be due to the decreased fidelity and 
therefore higher mutation rate of the WNV-AUS60 RdRp.  Our data suggest that 
both WNV-NY and WNV-AUS60 produce similar numbers of viral particles, 
while the WNV-AUS60 particles have significantly lower infectivity than the 
WNV-NY particles. 
The fidelity of WNV-AUS60 and WNV-NY RdRps could be measured as 
outlined by Pugachev et al. [204].  They measured Flavivirus RdRp fidelity with 
the use of infectious clones.  Most RNA viruses exist as a quasispecies since they 
replicate with high error rates and display genetic diversity [205].  Transfecting 
cells with an infectious clone can control the natural genetic diversity.  After the 
transfected virus establishes an infection within cultured cells, it can be serially 
passaged and plaque purified.  Finally, virus isolated from various passages and 
plaque purifications can be sequenced to compare mutations in the genome from 
one passage to the next.  While Pugachev et al. determined that the yellow fever 
virus RdRp has high fidelity [204], the RdRps of other RNA viruses, such as 
poliovirus have demonstrated low fidelity [206, 207].  If the fidelity of the WNV-
AUS60 RdRp is lower than the WNV-NY RdRp, this could explain why so many 




AUS60 RdRp is higher than that of WNV-NY, it could prove to be a potential 
vaccine candidate.  A study using poliovirus by Vignuzzi et al. demonstrated that 
viruses with higher fidelity RNA polymerases are restrained in their ability to 
mutate toward a higher-fitness genotype [208].  By enhancing replication fidelity, 
the strains are less likely to mutate and revert to wild type.  They are also 
restricted in their ability to spread to various tissues throughout the body. 
Since the virulence determinant separating WNV-NY from WNV-AUS60 
has not yet been identified, it is relevant to continue to compare these two strains.  
Because they are both within lineage one of the five phylogenetic lineages and 
display significantly different levels of pathogenicity in mice [59], their 
differences could be useful in the development of a WNV vaccine.  As many 
different steps within their viral life cycle could control their pathogenicity, it is 
important to consider the viral particle’s ability to bind to cells in addition to their 
ability to replicate.  
The particles produced by WNV-AUS60 infections could also be less 
effective at binding and entering cells.  If particles do not efficiently bind and 
enter cells, they cannot be infectious.  In order to attach to a cell, the E proteins on 
the WNV envelope must bind to a receptor on the target cell.  If the particle is 
immature or partially mature, the pr portion of prM covers the binding portion of 
E and it cannot bind cellular receptors. 
The production of an increased number of immature particles is another 
potential mechanism for controlling particle infectivity.  WNV-AUS60 infections 




WNV-AUS60 infections produce fewer infectious viral particles.  A possible 
explanation for the lower infectivity is that WNV-AUS60-infected cells may 
produce a greater number of immature particles.  At both 24 and 48 h post-
infection, levels of immature particle production could be assessed for both 
WNV-AUS60 and WNV-NY infections.  
In order for the particle to mature, the pr portion of prM is cleaved by a 
cellular furin-like protease in a low pH environment, within the TGN [83].  This 
cleavage exposes the fusion peptide on E and the E trimers rearrange into 
antiparallel dimers, which makes them fusion competent [84-86].  After 10 to 12 
hours in a mammalian cell, virions are finally exocytosed and mature particles or 
partially mature particles are capable of infecting other cells [22, 87]. 
To assess the effects of particle maturation, all viral particles could be 
induced in vitro to possess characteristics of mature virions as described by 
Stadler et al. [83].  Briefly, by exposing immature virions to recombinant 
bovine/human furin and low pH, prM can be cleaved to induce the characteristic 
structural rearrangement of mature virions.  Exposing WNV to these conditions 
will drive the particles toward maturation.  By inducing the mature conformation 
on both WNV-AUS60 and WNV-NY particles, their infectivity should be equal, 
if the decrease in WNV-AUS60 particle infectivity was due to higher levels of 





4. Final thoughts 
The work in this dissertation demonstrates that both IFN-dependent and 
IFN-independent mechanisms limit WNV infection in dermal fibroblasts, which 
are main components of an initial site of infection, the dermis.  This work 
determined that IFN-β is an integral part of the mechanism that controls WNV 
infection in dermal fibroblasts at late times post-infection.  This restriction at late 
times post-infection was a result of reduced particle infectivity.  The inhibitory 
effect of IFN on WNV infection of dermal fibroblasts could play a key role in the 
development of future antiviral therapies. The disparity between WNV-AUS60 
and WNV-NY particle infectivity remains unclear.  Once the mechanisms that 
inhibit WNV-AUS60 particle infectivity are determined, they could be used 




Chapter 5:  Materials and Methods 
 
1. Cells and viruses 
Vero, A549, and human foreskin fibroblast (HFF) (kindly provided by 
Alison McBride, NIH) cell lines were propagated at 37˚C in 5% CO2 in 
Dulbecco's Modified Eagle's Medium (DMEM) (Mediatech) supplemented with 
10% fetal bovine serum (FBS) (BioWhittaker), antibiotic/antimycotic solution, 
and nonessential amino acids (complete DMEM).  C6/36 cells were propagated at 
28˚C in 5% CO2 in Minimal Essential Medium (MEM) supplemented with 10% 
fetal bovine serum and antibiotic-antimycotic solution (complete MEM).  A 
WNV-NY strain 3356 stock was generated by passaging the infectious clone pFL-
WNV [157] once on HEK293 cells and twice on C6/36 cells. The WNV-AUS60 
stock was generated by plaque purifying clinical isolate MRM16, obtained from 
the World Reference Center of Emerging Viruses and Arboviruses (Galveston, 
TX), passaging it once on HEK293 cells and twice on C6/36 cells.  Titers for each 
stock were determined for each of the listed cell lines.  All WNV infections and 
handling of WNV-infected samples were carried out in Biosafety Level 3 (BSL3) 
biocontainment.  Vesicular stomatitis virus encoding green fluorescent protein 





2. Focus-forming assays 
HFFs were grown in 12-well tissue culture plates and infected with 
serially-diluted WNV-NY or WNV-AUS60.  After 1 h, inoculum was removed 
and replaced with complete DMEM in 10% methylcellulose.  At 24 h post-
infection, monolayers were washed three times with phosphate buffered saline 
(PBS) (Hyclone) and fixed with 3% paraformaldehyde for 30 min at room 
temperature. Cell monolayers were permeabilized with a solution of PBS/0.2% 
Triton X-100, blocked with PBS containing 1% normal goat serum, and incubated 
with WNV hyperimmune ascitic fluid (1:1000, World Reference Center of 
Emerging Viruses and Arboviruses) followed by Dylight 549nm-conjugated goat 
anti-mouse IgG (1:800, Jackson ImmunoLaboratories). Foci were visualized with 
an Olympus IX51 microscope.  
 
3. Virus growth curves   
Cell cultures were infected with WNV-NY or WNV-AUS60 (MOI=0.005 
or 0.05). The amount of virus added to cultures to achieve the indicated MOI was 
calculated using the titer of the viral stock as determined on HFFs. Cultures were 
incubated for 1 hour at 37oC with rocking, the inoculum was removed and 
complete DMEM was added.  Culture supernatants were recovered at the 
indicated times, clarified by low speed centrifugation for 5 minutes, transferred to 






4. Plaque assays 
Monolayers of Vero cells in six-well plates were inoculated with serial 
dilutions of viral samples.  The cells were incubated in a 5% CO2 incubator at 
37oC with rocking for 30 min (VSV) or 1 h (WNV). The inoculum was removed 
and a 0.9% agarose-complete DMEM overlay added. VSV plaques were counted 
24 hours post-infection. For WNV titration, cell monolayers were incubated for 
48 h and a second overlay of agarose-containing complete DMEM supplemented 
with 0.003% neutral red (ICN Biomedical) was added. The plates were incubated 
for an additional 48 (WNV-NY) to 72 hours (WNV-AUS60) prior to counting 
plaques. All titers were performed in duplicate. 
 
5. Quantitative reverse transcriptase-PCR 
Total RNA was extracted from HFFs infected with WNV using TRIzol 
reagent (Invitrogen Life Technologies, Inc) and treated with Turbo DNA-free 
(Invitrogen). RNA levels were determined by quantitative real-time PCR (qRT-
PCR) analysis on a Roche LC480 using Veriquest One-Step SYBR green 
MasterMix (Affymetrix Biosystems) with 25 ng of RNA. The following primers 
were used: WNV-NY(s): 5’ GGACCTTGTAAAGTTCCTATCTCG 3’; 
WNV-NY(as): 5’ AGGGTTGACAGTGACCAATC 3’;  
WNV-AUS60(s): 5’ GGACCCTGCAAGATACCCATTTC 3’;  
WNV-AUS60(as): 5’ GGGGTTGACGGTAACTAACC 3’;   
WNV lineage 1(s): 5’ TGGAACCACCCTTTGGAG 3’;  




human GAPDH(s): 5’ CCACTCCTCCACCTTTGAC 3’; 
human GAPDH(as): 5’ ACCCTGTTGCTGTAGCCA 3’;  
human IFN-β(s): 5’ ATGACCAACAAGTGTCTCCTCC 3’;  
human IFN-β(as): 5’ GCTCATGGAAAGAGCTGTAGTG 3’; 
human IFN-λ(s): 5’ GCCAAAGATGCCTTAGAAGAG 3’;  
human IFN-λ(as): 5’ CAGAACCTTCAGCGTCAGG 3’;  
human CXCL12(s): 5’ TGAGCTACAGATGCCCATGC 3’;  
human CXCL12(as): 5’ TTCTCCAGGTACTCCTGAATCC 3’. 
 
6. Immunofluorescence assay (IFA) 
HFFs were grown on coverslips and infected with WNV-AUS60 or WNV-
NY at an MOI of 0.005 or 0.05.  After 1 h, inoculum was removed and replaced 
with complete DMEM.  At 24 h post-infection, monolayers were washed with 
PBS (Hyclone) and fixed with 3% paraformaldehyde for 30 min at room 
temperature. Cell monolayers were permeabilized with a solution of PBS/0.2% 
Triton X-100, blocked with PBS containing 1% normal goat serum, and incubated 
with WNV hyperimmune ascitic fluid (1:1000, World Reference Center of 
Emerging Viruses and Arboviruses) followed by Dylight 549nm-conjugated goat 
anti-mouse IgG (1:800, Jackson ImmunoLaboratories) and Hoescht stain 
(0.1µg/mL). Foci were visualized with an Olympus IX51 microscope equipped 





7. Flow cytometry 
Cultures of HFFs grown on 6-well plates were infected with WNV at an 
MOI of 0.05.  At the indicated times post-infection, cells were removed from 
plates by trypsinization, washed twice with PBS and fixed in 3% 
paraformaldehyde. Cells were permeabilized with PBS/0.2% Triton X-100, 
blocked in PBS containing 0.5% heat-inactivated FBS and probed with WNV 
hyperimmune ascitic fluid (1:1000, World Reference Center of Emerging Viruses 
and Arboviruses) followed by DyLight 549 nm conjugated goat anti-mouse IgG 
(1:2000).  For flow cytometry analysis, 100,000 single cell events were collected 
using a FACS Canto (BD Biosciences). 
 
8. Immunoblot analysis 
Cells were washed twice with PBS and lysed in RIPA buffer (10 mM Tris, 
150 mM NaCl, 0.02% Na-deoxycholate, 1% Triton X-100, 0.1% sodium dodecyl 
sulfate [SDS]) containing protease inhibitors (Sigma).  Proteins (20 µg) were 
resolved on 10-12% polyacrylamide gels containing SDS and transferred to 
NitroPure nitrocellulose membranes (Micron Separations Inc.). Blots were 
blocked overnight at 4oC and probed with the following monoclonal or polyclonal 
antibodies: polyclonal rabbit anti-GAPDH (1:4000; Abcam), polyclonal mouse 
anti-WNV hyperimmune ascetic fluid (1:1000; World Reference Center of 
Emerging Viruses and Arboviruses), polyclonal rabbit anti-ISG56 (1:2000; kindly 
provided by Dr. Ganes Sen), polyclonal rabbit anti-ISG15 (1:2500; kindly 




Millipore), polyclonal rabbit anti-STAT-2 (1:1000; Santa Cruz), monoclonal 
mouse anti-phospho-STAT-1 (1:100; Santa Cruz), polyclonal mouse-anti-STAT-1 
(1:1000;Cell signaling), and polyclonal rabbit anti-IRF-9 (1:200; Santa Cruz).  
Following a secondary incubation with peroxidase-conjugated goat anti-rabbit or 
goat anti-mouse (Millipore) and treatment with ECL+ Western Blotting detection 
reagents (Amersham Biosciences), the protein bands were visualized by exposure 
of the membrane to film. 
 
9. UV-inactivation 
UV-inactivation was carried out by exposing a 1 ml aliquot of supernatant 
recovered form mock- or WNV-infected HFFs to UV (254 nm) for 2 min at room 
temperature in a Statalinker Model XL-1000 (Spectroincs Corp.).  Titers of UV-
treated supernatants were below detectible levels by plaque assay on Vero cells, 
confirming complete inactivation of the WNV-infected supernatants.  
 
10. Interferon bioassay 
A549 or HFF cells in 24-well plates were treated with two-fold serial 
dilutions of human IFN-β (BEI Resources) or cell-free, UV-inactivated 
supernatants recovered from mock or WNV-infected HFFs.  Cultures were 
incubated for 24 h at 37oC, infected with VSV (MOI=1) and supernatants were 
collected at 24 h post-infection. VSV titers were determined by plaque assay on 




standard curve generated from the titers of VSV recovered from samples treated 
with serial dilutions of IFN-β. 
 
11. Neutralization of type-I IFN 
The antibody concentration necessary to neutralize the IFN present in 
supernatants recovered from WNV-infected HFFs was determined by pretreating 
A549 cells for 24 hours with 25 IU/ml of IFN-α or IFN-β in the presence of 
2-fold serial dilutions of the antibodies to IFN- α (NR-3089; BEI resources) or 
IFN-β (NR-3091; BEI resources).  Control wells consisted of cells treated with 
IFN only, no IFN or isotype matched antisera to IFN-α or IFN-β. Pretreated cells 
were infected with VSV (MOI=1) and supernatants were collected at 24 h post-
infection.  Viral titers were determined by plaque assay on Vero cells. Culture 
supernatants were neutralized with twice the amount of antibody necessary to 
neutralize 25 IU/ml IFN-α or IFN-β or the appropriate control antisera (NR-3089 
or NR-3090; BEI resources) for 1 h at 37oC. For neutralization during WNV-
infection, HFFs were inoculated with WNV (MOI=0.05) for 1 hour at 37oC and 
the inoculum was replaced with complete DMEM containing neutralizing 
antibodies to IFN-α/IFN-β or the appropriate control antisera. In wells that 
contained supernatants to be collected at 48 h post-infection, supplemental 





12. Detection and enumeration of total virus particles 
Culture supernatants were cleared by low speed centrifugation for 5 
minutes and analyzed using the Virus Counter 2100 (ViroCyt LLC, Denver, CO) 
as per the manufacturer’s instructions. Briefly, samples were diluted 1:10 or 1:30 
to a total volume of 100 µl and incubated in the dark for 30 minutes with 50 µl of 
Combo dye, which stains nucleic acid and protein. Two-channel fluorescence was 
used to detect co-localization of nucleic acid and protein. Events with 
simultaneous detection within both channels were defined as virus particles by 
Virocyt software. 
 
13. Enzyme-linked immunosorbent assay (ELISA) 
TNF-α, CCL2, and CCL5 concentrations in culture supernatants from 
mock- and WNV-infected HFFs were determined by TNF-α (BD Biosciences), 
CCL2 (R&D systems), and CCL5 (R&D systems) ELISA kits as per 
manufacturer’s instructions.   Culture supernatants were UV-inactivated for 2 min 
then incubated on antibody-coated 96-well plates alongside serial dilutions of 
standards using the human TNF-α, CCL2, and CCL5 ELISA kits as per 
manufacturer’s instructions (BD Biosciences and R&D systems).   
 
14. Yield reduction assay (YRA) 
A549 cells in 12-well plates were infected with standard virus, WNV-NY, 




amount of virus added to cultures to achieve the indicated MOI was calculated 
using the titer of the viral stock as determined on A549s.  Cultures were incubated 
for 1 hour at 37oC with rocking, the inoculum was removed and complete DMEM 
was added.  Culture supernatants were recovered at 48 h post-infection, clarified 
by low speed centrifugation for 5 minutes, transferred to new tubes, and stored at 
-80oC. Viral titers were determined by plaque assay on Vero cells.  Plaques were 
counted at 72 h post-infection, which is when WNV-NY plaques are visible and 
WNV-AUS60 plaques are not. 
 
15. Statistical analysis 
Graphpad Prism 5 was used for all statistical analyses.  Comparative 
significance was determined with unpaired Student’s t-tests. 
 
16. Phylogenetic analysis 
The nucleic acid sequences for the E region of the genome of each WNV 
strain were obtained from GenBank with the following accession numbers: JEV: 
U0422; Egypt 1951: AF260968; C.Afr.Rep 1967: AF001566; NY 2000-
crow3356: AF404756; NY 1999-human: AF202541; Israel 1998-A: AY033389; 
Romania 1996 M: AF260969; Italy 1998: AF404757; Australia 1960: GQ851602; 
India 1980: DQ256376; Madagascar 1978: AF001559; C. Afr.Rep 1972a: 
AF001563; Uganda 1937: M12294; Austria 1997: AY765264; Russia 1998: 




version 10.0.2 (MacVector, Inc., Cambridge, United Kingdom).  The nearest 
neighbor joining tree was developed within MacVector using the Tamura-Nei 
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